Safest SSRI or SNRI in Pregnancy
Sertraline is the safest SSRI for use during pregnancy, with the lowest risk profile for persistent pulmonary hypertension of the newborn (PPHN) and established safety data, while paroxetine should be avoided due to FDA pregnancy category D classification for cardiac malformations. 1, 2
Primary Recommendation: Sertraline
Sertraline ranks as most likely to have the lowest risk for PPHN among SSRIs (P = .83) according to network meta-analysis, suggesting it has the best safety profile for pregnancy use 2. Additionally, sertraline is one of the most commonly prescribed antidepressants during both pregnancy and breastfeeding, reflecting its established safety record 1.
Medications to Avoid
Paroxetine carries the highest risk and should be avoided:
- FDA classified paroxetine as pregnancy category D in 2005 due to concerns about congenital cardiac malformations 1
- While more recent population-based studies (nearly 1 million pregnant women) suggest no link between first-trimester antidepressant use and cardiac malformations, the FDA classification remains 1
Class-Wide Risks to Discuss
All SSRIs and SNRIs carry some shared risks that must be weighed against untreated depression:
Persistent Pulmonary Hypertension of the Newborn (PPHN)
- Risk increases with late pregnancy exposure (after 20 weeks): OR 2.08 (95% CI, 1.44-3.01) 2
- Incidence: 2.9 cases per 1000 live births
- Number needed to harm: 286-351 1
- Critical caveat: FDA revised its 2006 advisory in 2011, stating conflicting findings make it unclear whether SSRIs actually cause PPHN 1
Neonatal Adaptation Syndrome
- Occurs in hours to days after birth
- Symptoms: continuous crying, irritability, jitteriness, tremors, hypertonia, tachypnea, feeding difficulty, hypoglycemia, seizures 3
- Usually resolves within 1-2 weeks (up to 4 weeks with paroxetine) 3
Other Potential Risks
- May increase risk of preterm delivery compared to untreated depressed women 1
- Conflicting evidence on autism, ADHD, speech delay, and lower Apgar scores—high-quality evidence lacking 1
SNRIs in Pregnancy
SNRIs (duloxetine, venlafaxine) have slightly higher discontinuation rates due to adverse effects compared to SSRIs as a class (67% and 40% increased risk respectively) 1. Given limited pregnancy-specific data and higher side effect burden, SSRIs remain preferred first-line agents.
Clinical Algorithm
- First choice: Sertraline (lowest PPHN risk, extensive safety data)
- Alternative SSRIs: Fluoxetine, citalopram, escitalopram (avoid citalopram >40 mg/day due to QT prolongation) 1
- Avoid: Paroxetine (FDA category D)
- SNRIs: Reserve for cases where SSRIs have failed or are contraindicated
Essential Management Principles
- Use monotherapy at the lowest effective dose 4
- Consider therapeutic drug monitoring (TDM) during pregnancy due to pharmacokinetic changes across trimesters 4
- Do not discontinue antidepressants in women with severe, recurrent depression—relapse risk is substantial 4
- Arrange delivery at hospitals with specialized neonatal care units 4
- Plan early follow-up after discharge to monitor for neonatal adaptation syndrome (first week of life) 3
Critical Context
Untreated depression carries significant risks: premature birth, decreased breastfeeding initiation, and ongoing maternal morbidity 1. The absolute risks from SSRI exposure remain small, and treatment decisions must balance medication risks against the substantial harms of untreated maternal depression. The risk of relapse with medication discontinuation often outweighs the small absolute risks of continued treatment 4.